StockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX)

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research report released on Monday morning. The firm issued a sell rating on the stock.

Other research analysts have also issued research reports about the company. D. Boral Capital restated a “buy” rating and set a $5.00 price objective on shares of VolitionRx in a research report on Thursday, February 6th. Benchmark restated a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd.

VolitionRx Stock Performance

VNRX opened at $0.56 on Monday. The stock has a market capitalization of $52.08 million, a price-to-earnings ratio of -1.56 and a beta of 1.20. The company has a fifty day moving average of $0.61 and a 200 day moving average of $0.65. VolitionRx has a fifty-two week low of $0.43 and a fifty-two week high of $1.10.

Insiders Place Their Bets

In related news, CEO Cameron John Reynolds acquired 139,811 shares of the firm’s stock in a transaction on Monday, December 9th. The shares were acquired at an average cost of $0.57 per share, for a total transaction of $79,692.27. Following the completion of the transaction, the chief executive officer now directly owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Guy Archibald Innes bought 174,764 shares of the company’s stock in a transaction dated Monday, December 9th. The stock was bought at an average price of $0.57 per share, with a total value of $99,615.48. Following the acquisition, the director now owns 617,085 shares in the company, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired 358,266 shares of company stock valued at $204,212 in the last three months. Corporate insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Millennium Management LLC bought a new stake in shares of VolitionRx in the 4th quarter worth about $36,000. Lagoda Investment Management L.P. raised its position in VolitionRx by 24.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after purchasing an additional 1,481,000 shares during the period. Northern Trust Corp lifted its stake in VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after purchasing an additional 28,579 shares during the last quarter. Two Sigma Securities LLC purchased a new position in shares of VolitionRx during the fourth quarter valued at approximately $29,000. Finally, Geode Capital Management LLC grew its stake in shares of VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after buying an additional 95,900 shares during the last quarter. Institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.